Recommendations for the use of botulinum toxin type A in the management of cerebral palsy

被引:265
作者
Graham, HK
Aoki, KR
Autti-Rämö, I
Boyd, RN
Delgado, MR
Gaebler-Spira, DJ
Gormley, ME
Guyer, BM
Heinen, F
Holton, AF
Matthews, D
Molenaers, G
Motta, F
Ruiz, PJG
Wissel, J
机构
[1] Royal Childrens Hosp, Dept Orthopaed Surg, Melbourne, Vic 3052, Australia
[2] Allergan Pharmaceut Inc, Irvine, CA USA
[3] Univ Helsinki, Hosp Children & Adolescents, Helsinki, Finland
[4] Royal Childrens Hosp, Hugh Williamson Gait Anal Lab, Melbourne, Vic, Australia
[5] Texas Scottish Rite Hosp Children, Dallas, TX 75219 USA
[6] Northwestern Univ, Sch Med, Dept Clin Phys Med & Rehabil, Chicago, IL 60608 USA
[7] Gillette Childrens Hosp, Dept Phys Med & Rehabil, St Paul, MN USA
[8] DuoMed Ltd, Wokingham, England
[9] Univ Freiburg, Childrens Hosp, Dept Neuropaediat, Freiburg, Germany
[10] Leicester Royal Infirm, Dept Paediat, Leicester, Leics, England
[11] Denver Childrens Hosp, Dept Rehabil, Denver, CO USA
[12] Univ Ziekenhuizen, Dept Orthopaed, Pellenberg, Belgium
[13] Osped Bambini V Buzzi, Inst Clin Perfezionamento, Milan, Italy
[14] Fdn Jimenez Diaz, Dept Neurol, E-28040 Madrid, Spain
[15] Univ Innsbruck, Neurol Clin, A-6020 Innsbruck, Austria
关键词
cerebral palsy; botulinum toxin type A; BOTOX (R); guidelines; consensus document;
D O I
10.1016/S0966-6362(99)00054-5
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Botulinum toxin type A (BTX-A) is increasingly bring used for the treatment of childhood spasticity, particularly cerebral palsy. However, until very recently, all such use in this indication has been unapproved with no generally accepted treatment protocols, resulting in considerable uncertainty and variation in its use as a therapeutic agent. In view of the increasing awareness of, and interest in, this approach to the treatment of spasticity, and also the recent licensing in a number of countries of a BTX-A preparation fnr treating equinus deformity in children, it would seem timely to establish a framework of guidelines for the safe and efficacious use of BTX-A for treating spasticity in children. This paper represents an attempt, by a group of 15 experienced clinicians and scientists from a variety of disciplines, to arrive at a consensus and produce detailed recommendations as to appropriate patient selection and assessment, dosage, injection technique and outcome measurement. The importance of adjunctive physiotherapy, orthoses and casting is also stressed. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:67 / 79
页数:13
相关论文
共 52 条
[1]   MOLECULAR ASPECTS OF TETANUS AND BOTULINUM NEUROTOXIN POISONING [J].
AHNERTHILGER, G ;
BIGALKE, H .
PROGRESS IN NEUROBIOLOGY, 1995, 46 (01) :83-96
[2]  
ANDERSON TJ, 1992, J ROY SOC MED, V85, P524
[3]   TERMINAL SPROUTING IN MOUSE NEUROMUSCULAR-JUNCTIONS POISONED WITH BOTULINUM TYPE-A TOXIN - MORPHOLOGICAL AND ELECTROPHYSIOLOGICAL FEATURES [J].
ANGAUTPETIT, D ;
MOLGO, J ;
COMELLA, JX ;
FAILLE, L ;
TABTI, N .
NEUROSCIENCE, 1990, 37 (03) :799-808
[4]  
[Anonymous], 1995, OCCUPATIONAL THERAPY
[5]  
[Anonymous], 1996, GAIT POSTURE
[6]  
Aoki KR, 1997, EUR J NEUROL, V4, pS1
[7]  
AOKI KR, 1999, IN PRESS EUR J NEURO
[8]   ABSENCE OF ANTIBODY-PRODUCTION IN PATIENTS TREATED WITH BOTULINUM-A TOXIN [J].
BIGLAN, AW ;
GONNERING, R ;
LOCKHART, LB ;
RABIN, B ;
FUERSTE, FH .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1986, 101 (02) :232-235
[9]   BOTULINUM NEUROTOXIN-A SELECTIVELY CLEAVES THE SYNAPTIC PROTEIN SNAP-25 [J].
BLASI, J ;
CHAPMAN, ER ;
LINK, E ;
BINZ, T ;
YAMASAKI, S ;
DECAMILLI, P ;
SUDHOF, TC ;
NIEMANN, H ;
JAHN, R .
NATURE, 1993, 365 (6442) :160-163
[10]   INTERRATER RELIABILITY OF A MODIFIED ASHWORTH SCALE OF MUSCLE SPASTICITY [J].
BOHANNON, RW ;
SMITH, MB .
PHYSICAL THERAPY, 1987, 67 (02) :206-207